Last reviewed · How we verify

Alogliptin and insulin

Takeda · Phase 3 active Small molecule

Alogliptin and insulin is a DPP-4 inhibitor combined with insulin Small molecule drug developed by Takeda. It is currently in Phase 3 development for Type 2 diabetes mellitus in patients inadequately controlled on insulin alone. Also known as: alogliptin, SYR110322.

Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glucose control, while insulin provides exogenous glucose-lowering activity.

Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glucose control, while insulin provides exogenous glucose-lowering activity. Used for Type 2 diabetes mellitus in patients inadequately controlled on insulin alone.

At a glance

Generic nameAlogliptin and insulin
Also known asalogliptin, SYR110322
SponsorTakeda
Drug classDPP-4 inhibitor combined with insulin
TargetDPP-4 (dipeptidyl peptidase-4)
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Alogliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing insulin secretion and reducing glucagon in response to elevated blood glucose. The combination with insulin provides additional glycemic control through exogenous insulin replacement, targeting both endogenous and exogenous pathways of glucose homeostasis in type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Alogliptin and insulin

What is Alogliptin and insulin?

Alogliptin and insulin is a DPP-4 inhibitor combined with insulin drug developed by Takeda, indicated for Type 2 diabetes mellitus in patients inadequately controlled on insulin alone.

How does Alogliptin and insulin work?

Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glucose control, while insulin provides exogenous glucose-lowering activity.

What is Alogliptin and insulin used for?

Alogliptin and insulin is indicated for Type 2 diabetes mellitus in patients inadequately controlled on insulin alone.

Who makes Alogliptin and insulin?

Alogliptin and insulin is developed by Takeda (see full Takeda pipeline at /company/takeda).

Is Alogliptin and insulin also known as anything else?

Alogliptin and insulin is also known as alogliptin, SYR110322.

What drug class is Alogliptin and insulin in?

Alogliptin and insulin belongs to the DPP-4 inhibitor combined with insulin class. See all DPP-4 inhibitor combined with insulin drugs at /class/dpp-4-inhibitor-combined-with-insulin.

What development phase is Alogliptin and insulin in?

Alogliptin and insulin is in Phase 3.

What are the side effects of Alogliptin and insulin?

Common side effects of Alogliptin and insulin include Hypoglycemia, Nasopharyngitis, Upper respiratory tract infection, Headache, Pancreatitis.

What does Alogliptin and insulin target?

Alogliptin and insulin targets DPP-4 (dipeptidyl peptidase-4) and is a DPP-4 inhibitor combined with insulin.

Related